Pemphigus
27
4
5
9
Key Insights
Highlights
Success Rate
60% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 65/100
22.2%
6 terminated out of 27 trials
60.0%
-26.5% vs benchmark
22%
6 trials in Phase 3/4
67%
6 of 9 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 9 completed trials
Clinical Trials (27)
A Clinical Study of B007 in the Treatment of Pemphigus.
Comparison of a Personalized Maintenance Therapy With the Standard Treatment in Pemphigus
FARD (RaDiCo Cohort) (RaDiCo-FARD)
Identification of Vulnerability Factors in the Course of Pemphigus Patients
ONO-4059 Study in Patients With Steroid-resistant Pemphigus
IVIG With Rituximab vs Rituximab as First Line Treatment of Pemphigus
A Single-center Study of CM313 in Patients With Pemphigus
Efficacy and Safety Evaluation of Anti-CD20 Monoclonal Antibody Combined with Azathioprine and Corticosteroids in the Treatment of Pemphigus Vulgaris
Coagulation Activation in Patients With Pemphigus
A Study of PRN1008 in Patients With Pemphigus
Validation of 5-Point Investigator Global Assessments for Pemphigus
Human Leukocyte Antigen Class II (DRB1 and DQB1) Alleles and Haplotypes Frequencies in Patients With Pemphigus Vulgaris Among the Russian Population
A Safety and Dose-Finding Study of SYNT001 in Subjects With Pemphigus (Vulgaris or Foliaceus)
Role of Proteasomes in a Dermatological Autoimmune Disease: Bullous Pemphigoid
Use of Infliximab for the Treatment of Pemphigus Vulgaris
Long-Term Extension Study of Ofatumumab in Subjects With Pemphigus Vulgaris
Evaluating Sirolimus to Treat Autoimmune Blistering Dermatosis Pemphigus
Immunoadsorption, Dexamethasone Pulse Therapy and Rituximab for Pemphigus
Wound Dressings for Pemphigus and Pemphigoid
Comparative Study of Rituximab Versus Combination of Rituximab and Intravenous Cyclophosphamide in Severe Pemphigus